Fibrous Dysplasia: A Comprehensive Guide
What is Fibrous dysplasia?
Fibrous dysplasia is a rare skeletal disorder where normal bone and bone marrow are replaced by fibrous tissue and abnormal bone. This condition exists on a spectrum, ranging from isolated bone lesions to McCune-Albright syndrome (MAS), which includes additional features like distinctive skin pigmentation and hormone problems. The condition is caused by mosaic mutations in the GNAS gene, meaning the genetic change occurs after conception and affects only some cells in the body. While exact prevalence figures vary, fibrous dysplasia affects an estimated 1 in 15,000 to 1 in 30,000 people worldwide.
Key statistics
| Prevalence: | 1 in 15,000 to 1 in 30,000 people |
| Age of onset: | Usually childhood to early adulthood |
| Gender distribution: | Affects males and females equally |
| Inheritance pattern: | Not inherited (sporadic mosaic mutation) |
Symptoms
Common symptoms include: bone pain, fractures, bone deformities, café-au-lait skin spots, precocious puberty, limping, facial asymmetry.
The symptoms of fibrous dysplasia vary significantly depending on which bones are affected and whether additional features of McCune-Albright syndrome are present. Bone-related symptoms typically appear first and include persistent bone pain, particularly in weight-bearing bones like the femur and tibia. Fractures may occur with minimal trauma due to weakened bone structure. Progressive bone deformities can develop, including bowing of the legs, facial asymmetry, and shortening of affected limbs.
When fibrous dysplasia is part of McCune-Albright syndrome, patients also develop characteristic café-au-lait macules—irregular brown skin spots with jagged borders, often described as having a “coast of Maine” appearance. Endocrine abnormalities are another hallmark, most commonly precocious puberty in girls, but may also include hyperthyroidism, growth hormone excess, and Cushing syndrome. Some patients experience hearing loss or vision problems when skull bones are involved.
Causes and risk factors
Fibrous dysplasia is caused by mosaic mutations in the GNAS gene, which provides instructions for making a protein involved in cell signaling. These mutations occur spontaneously after conception, during early embryonic development, which explains why only certain cells and tissues are affected. The mutation disrupts normal bone formation, leading to the replacement of healthy bone with fibrous tissue and abnormal bone.
Because the condition results from a postzygotic mutation (occurring after fertilization), it is not inherited from parents and cannot be passed to children through traditional inheritance patterns. There are no known environmental risk factors or preventable causes. The extent and severity of the condition depend on when during development the mutation occurred and how widely it spread to different cell lines.
Prevention
Because fibrous dysplasia results from spontaneous genetic mutations that occur after conception, there are no known prevention methods. The condition is not inherited from parents, so family history does not increase risk, and genetic counseling for family planning is typically not necessary. However, individuals with fibrous dysplasia should receive genetic counseling to understand the minimal risk of transmission to their children.
Prenatal testing is not routinely available or recommended since the mutations are not present in parental genetic material. Focus should instead be placed on early recognition of symptoms and prompt medical evaluation when concerning signs develop.
Complications
Without proper management, fibrous dysplasia can lead to several serious complications. Repeated fractures and progressive bone deformities may result in significant disability and mobility limitations. Skull involvement can cause facial deformity, dental problems, hearing loss, and vision impairment. In severe cases, spinal involvement may lead to scoliosis or nerve compression.
When associated with McCune-Albright syndrome, endocrine complications can be particularly problematic. Untreated precocious puberty may result in short adult stature due to premature growth plate closure. Hyperthyroidism can cause heart problems, while growth hormone excess may lead to gigantism or acromegaly. Rarely, the fibrous tissue may undergo malignant transformation to osteosarcoma, though this occurs in less than 1% of cases.
Diagnosis
Diagnosing fibrous dysplasia requires a combination of clinical evaluation, imaging studies, and sometimes genetic testing. X-rays typically show characteristic “ground glass” appearing lesions in affected bones. CT scans provide more detailed bone structure assessment, while MRI can help evaluate soft tissue involvement and rule out malignancy.
Bone biopsy may be performed in uncertain cases, revealing the characteristic fibrous tissue replacement of normal bone and marrow. For McCune-Albright syndrome, hormone level testing is essential, including growth hormone, thyroid function, cortisol, and reproductive hormones. Genetic testing for GNAS mutations can confirm the diagnosis, though it may be negative in some cases due to the mosaic nature of the condition.
Bone turnover markers like alkaline phosphatase may be elevated. Ophthalmologic and audiologic evaluations are recommended when skull bones are involved.
Treatment
Treatment for fibrous dysplasia focuses on managing symptoms and preventing complications. Bisphosphonates are commonly prescribed to reduce bone pain and may help strengthen affected bones. Pamidronate and zoledronic acid have shown particular benefit in reducing pain and bone turnover markers.
Surgical intervention may be necessary for fractures, severe deformities, or functional impairment. Procedures range from simple fracture repair to complex reconstructive surgeries using bone grafts or internal fixation devices. Denosumab, a newer bone-targeting therapy, has shown promise in some patients who don’t respond to bisphosphonates.
For McCune-Albright syndrome, endocrine abnormalities require specific treatments. Precocious puberty may be managed with GnRH analogs, while hyperthyroidism requires antithyroid medications or surgery. Growth hormone excess may need treatment with somatostatin analogs.
Prognosis
The prognosis for fibrous dysplasia varies significantly depending on the extent and location of bone involvement. Many patients with limited disease live normal lives with minimal symptoms. Those with more extensive involvement may experience ongoing challenges with bone pain, fractures, and deformities, but with appropriate treatment, most can maintain good quality of life.
Life expectancy is generally normal, though complications from extensive craniofacial involvement or malignant transformation can be serious. Early diagnosis and treatment significantly improve outcomes. The condition typically stabilizes after puberty, with less active bone turnover and fewer new lesions developing in adulthood.
Quality of life
Living with fibrous dysplasia requires ongoing attention to bone health and symptom management. Regular exercise, particularly low-impact activities like swimming and cycling, can help maintain bone strength and overall fitness while minimizing fracture risk. A diet rich in calcium and vitamin D supports bone health.
Pain management strategies may include physical therapy, occupational therapy, and stress reduction techniques. Many patients benefit from assistive devices for mobility when needed. Mental health support is important, as chronic pain and physical differences can impact self-esteem and social interactions, particularly in children and adolescents.
Work and school accommodations may be necessary for those with significant mobility limitations or frequent medical appointments. Patient advocacy groups provide valuable peer support and practical advice for daily living challenges.
Pregnancy and fertility
Fertility is generally not directly affected by fibrous dysplasia itself, though some endocrine abnormalities associated with McCune-Albright syndrome may impact reproductive function. Pregnancy planning should involve consultation with specialists familiar with the condition.
During pregnancy, bisphosphonate therapy is typically discontinued due to potential fetal risks. Pain management may require alternative approaches. Women with pelvic bone involvement may need careful monitoring and potentially cesarean delivery. Genetic counseling can provide reassurance about the very low risk of transmission to children.
Children
Fibrous dysplasia often first manifests in childhood, making pediatric care particularly important. Children may present with limping, bone pain, or fractures after minor trauma. Growth and development should be carefully monitored, especially when endocrine abnormalities are present.
School accommodations may be needed for children with mobility limitations or frequent medical appointments. Psychosocial support helps children cope with physical differences and build confidence. Family education about activity modifications and when to seek medical attention is crucial.
When to see a doctor
Immediate medical attention is needed for suspected fractures, severe bone pain, sudden hearing or vision changes, or signs of nerve compression like numbness or weakness. Parents should consult pediatricians if children show signs of early puberty, unusual bone pain, or distinctive skin spots.
Routine follow-up with specialists is important for monitoring disease progression and treatment effectiveness. Regular endocrine evaluation is essential for those with McCune-Albright syndrome features.
Regional context
Limited specific data exists regarding fibrous dysplasia prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) or Eastern Mediterranean. The condition appears to affect all ethnic groups equally, suggesting similar prevalence rates globally. Healthcare providers in these regions are encouraged to contribute case data and research to improve understanding of regional disease patterns. The Global Medical Journal welcomes submissions from regional medical professionals regarding their experience with fibrous dysplasia management and outcomes.
Research and clinical trials
Current research focuses on better understanding GNAS mutations and developing targeted therapies. Studies are investigating new bone-strengthening medications, improved surgical techniques, and treatments for associated endocrine abnormalities. Gene therapy approaches are being explored in laboratory settings.
Recent breakthroughs include better understanding of the molecular pathways involved and development of more specific treatments for McCune-Albright syndrome features. Patients can find current clinical trials at ClinicalTrials.gov by searching “fibrous dysplasia” or “McCune-Albright syndrome.”
Frequently asked questions
Is fibrous dysplasia inherited?
No, fibrous dysplasia results from spontaneous mutations that occur after conception and is not passed from parents to children through traditional inheritance patterns.
Will my fibrous dysplasia get worse over time?
Disease activity typically decreases after puberty, though existing lesions may persist. Regular monitoring helps track any changes and adjust treatment accordingly.
Can I exercise with fibrous dysplasia?
Yes, but activity modifications may be needed. Low-impact exercises are generally recommended, while contact sports or activities with high fracture risk should be avoided.
What is the difference between fibrous dysplasia and McCune-Albright syndrome?
McCune-Albright syndrome includes fibrous dysplasia plus café-au-lait skin spots and endocrine abnormalities like precocious puberty. Fibrous dysplasia alone affects only bones.
Is there a cure for fibrous dysplasia?
There is no cure, but treatments can effectively manage symptoms, reduce pain, and prevent complications. Many patients live normal, productive lives with appropriate care.
Support and resources
- Fibrous Dysplasia Foundation – Primary patient advocacy organization
- Orphanet – European reference portal for rare diseases
- National Organization for Rare Disorders (NORD)
- EURORDIS – European Organisation for Rare Diseases
- World Health Organization – Global health information
Related conditions
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Fibrous dysplasia.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/fibrous-dysplasia/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?